A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Abstract Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in 2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is very limited, this study evaluated capmatinib-induced adverse events through data mining of the FDA Adverse Eve...
Zapisane w:
| Główni autorzy: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Nature Portfolio
2024-05-01
|
| Seria: | Scientific Reports |
| Dostęp online: | https://doi.org/10.1038/s41598-024-62356-w |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|